OpenAI is making more than $1 billion a month from something that has nothing to do with ChatGPT

OpenAI has achieved a remarkable milestone, generating over a billion dollars in revenue in just one month, primarily through its API services. CEO Sam Altman shared this exciting news via a post on X, highlighting that the API sector has contributed significantly to the company's annual recurring revenue. Often recognized for ChatGPT, Altman emphasized that the API team at OpenAI is delivering exceptional results. The API allows companies and developers to integrate OpenAI's sophisticated models into their own applications, ranging from productivity tools to software for coding. Notably, several prominent startups in Silicon Valley depend on OpenAI's technology as a fundamental part of their infrastructure. For instance, Perplexity leverages OpenAI's models to enhance its AI-driven search and response platform, while Harvey, a rapidly growing legal tech startup, utilizes these models to aid lawyers in research and drafting processes. Altman’s remarks highlight the burgeoning significance of OpenAI’s API business as a vital growth driver, especially amidst the substantial expenses associated with computing resources and data center operations. This financial pressure has prompted OpenAI to explore revenue avenues beyond consumer subscriptions. Recently, the company announced plans to trial advertising within ChatGPT as it grapples with approximately $1.4 trillion in future expenditure commitments—a notable pivot for a firm that previously viewed advertising as a last resort. In a striking evolution of perspective, Altman previously expressed discomfort with ads in a discussion at Harvard University, labeling them as unsettling. However, he has since adopted a more flexible attitude. In a recent podcast episode, he indicated that while he isn't outright opposed to advertising, it must be handled with care. Additionally, OpenAI's CFO, Sarah Friar, proposed the concept of licensing models, which would allow the company to benefit from successful downstream sales of products that utilize their technology, such as breakthroughs in drug discovery.